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Despite years of work aimed at improv-
ing the prognosis of glioblastoma (GBM) 
patients, overall survival has remained 
largely unchanged. Novel approaches 
against this dreadful disease encompass 
the use of targeted anticancer agents to 
inhibit aberrant signaling pathways, anti-
angiogenic agents, immunotherapy and 
virotherapy. In the latter setting, non-
replicating viral vectors are used either to 
introduce exogenous transgenes or to pro-
mote antitumor immune responses. An 
alternative strategy for virotherapy relies 
on replicating oncolytic viruses that selec-
tively infect tumor cells, eventually result-
ing in their lysis.
Phase I clinical trials studying onco-
lytic virotherapy in GBM patients have 
demonstrated the safety of this approach.1 
However, preliminary indications of effi-
cacy have been disappointing. Thus, efforts 
have been dedicated at identifying barriers 
that would reduce the efficacy of oncolytic 
viruses as well as at designing second-gen-
eration viruses that can circumvent such 
impediments. Examples of processes that 
interfere with virotherapy include, but are 
not limited to, the interferon response that 
normally follows viral infection, the viral 
clearance mediated by the innate immune 
system, and the blockage of viral dissemi-
nation within the tumor as mediated by 
the extracellular matrix.2
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The deleterious impact of innate immu-
nity in virotherapy was first identified in 
preclinical animal studies demonstrating 
that the combination of cyclophosphamide 
(CPA) with an oncolytic herpes simplex 
virus (oHSV) significantly improves sur-
vival.3 Immunohistochemical studies of 
tumor-bearing rats treated with CPA and 
oHSV unveiled a significant reduction in 
the number of macrophages, microglial 
cells, and natural killer (NK) cells within 
the tumor microenvironment, which cor-
related with increased viral replication.4 
Additionally, the efficacy of CPA combined 
with oHSV was improved in mice pre-
treated with clodronate liposomes (which 
deplete macrophages) as well as in animals 
genetically deficient for interferon γ.4,5
As they are endowed with both antivi-
ral and antitumor functions, at least hypo-
thetically NK cells may either inhibit the 
efficacy of virotherapy or promote addi-
tional degrees to tumor-cell killing, result-
ing in improved antineoplastic effects. 
Using the vesicular stomatitis virus (VSV) 
for the treatment of hepatocellular carci-
noma, Altomonte et al. demonstrated that 
the depletion of NK cells enhances viral 
efficacy and increases overall survival.6 A 
subsequent study was based on a second 
generation oncolytic VSV encoding a che-
mokine-binding protein that limits NK 
and NKT cell intratumoral infiltration, 
resulting in improved efficacy.7 While 
these findings suggest that NK cells consti-
tute an initial barrier to viral oncolysis, sev-
eral groups have highlighted the necessity 
of harnessing the antitumor properties of 
these cells to achieve tumor clearance.8 In 
this context, by using both xenograft and 
syngeneic mouse glioma models Alvarez-
Breckenridge et al. have recently demon-
strated the relevance of NK cells following 
oHSV infection (Fig. 1).9 Indeed, follow-
ing the intracranial inoculation of oHSV, 
NK cells were recruited into the brain and 
manifested an activated phenotype. In 
addition, NK cells were found to mediate 
the inflammatory cytokine and chemo-
kine milieu that stems from viral infection 
while coordinating the activation of mac-
rophage and microglial cells. Confirming 
the functional relevance of these find-
ings, the survival of mice bearing either 
U87dEGFR glioma xenografts or 4C8 
murine gliomas increased upon the deple-
tion of NK cells prior to oHSV infection. 
These findings suggest that—presumably 
owing to their antiviral functions—NK 
cells play an important role in limiting 
the efficacy of oHSV-based therapeutic 
approaches against GBM.
To further understand the mechanisms 
underlying these observations, NK cell-
mediated cytotoxicity was determined in 
vitro by co-culturing human NK cells with 
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not be overlooked. Indeed, to achieve 
successful therapeutic responses upon 
virotherapy, there must be a delicate bal-
ance between the antiviral and antitumor 
immunity. Mathematical modeling has 
proposed that shortly after infection, the 
innate immune system should be sup-
pressed to achieve multiple rounds of viral 
replication.10 Once a sufficient viral load is 
attained to achieve tumor killing, antitu-
mor immune effectors including NK cells 
may constitute a valuable partner for tumor 
clearance. The challenge for future studies 
will be to identify both a mechanism and a 
time point for switching from the suppres-
sion of antiviral immunity to the activation 
of antitumor immune responses.
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to assess if these preclinical findings can 
be translated into a clinical setting. In 
particular, it will be important to deter-
mine if human NK cells infiltrate the 
tumor microenvironment upon infection 
by oncolytic viruses; to isolate tumor-
infiltrating and circulating NK cells and 
determine their functional profile; and 
to correlate NK cell, macrophagic and 
microglial responses with the survival of 
patients subjected to virotherapy. From a 
preclinical perspective, future studies will 
have to identify the NKp30 and NKp46 
ligands that are upregulated in response to 
oHSV infection, as the blockage of recep-
tor-ligand interactions may have impor-
tant therapeutic implications.
While the work by Alvarez-Breckenridge 
et al. highlights a deleterious role of NK 
cells in the context of virotherapy, the 
importance of antitumor immunity should 
distinct human glioma cell lines. Of note, 
NK cell-mediated killing was significantly 
enhanced when tumors were initially 
infected with oHSV. By means of a panel 
of blocking antibodies, natural cytotoxic-
ity receptors, notably NKp30 and NKp46, 
were identified as critical mediators of 
this response, which was paralleled by 
an increased expression on the tumor cell 
surface of NKp30 and NKp46 ligands. 
In line with these findings, intracranially 
inoculated oHSV exhibited elevated rates 
of replication in NKp46-deficient glioma-
bearing mice, and increased the survival 
of these animals to higher extents than 
that of wild-type mice.
The study by Alvarez-Breckenridge 
et al. is the first to provide a potential 
mechanism whereby NK cells constitute 
an initial barrier to oHSV-based therapy 
(Fig. 1). Future clinical trials will need 
Figure 1. Deleterious role of natural killer cells in virotherapy. (A) Glioma cells normally express ligands for the natural killer (NK) cell natural cytotoxic-
ity receptors NKp30 and NKp46. (B and C) upon infection by oncolytic herpes simplex virus (ohsV), these ligands are overxpressed, correlating with 
a temporal increase in NK cell activation within the tumor microenvironment. NK cells kill ohsV-infected glioma cells via NKp30 and NKp46, in turn 
resulting in decreased viral titers and limiting the efficacy of viral oncolysis.www.landesbioscience.com OncoImmunology  e23658-3
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